CIBC Private Wealth Group LLC Has $375.01 Million Stock Position in Danaher Co. (NYSE:DHR)

CIBC Private Wealth Group LLC cut its position in Danaher Co. (NYSE:DHR) by 3.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,575,076 shares of the conglomerate’s stock after selling 52,526 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Danaher were worth $375,010,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Heck Capital Advisors LLC bought a new position in shares of Danaher in the fourth quarter worth about $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the 4th quarter worth approximately $31,000. Golden State Wealth Management LLC acquired a new position in shares of Danaher during the fourth quarter worth approximately $31,000. Pineridge Advisors LLC boosted its position in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 57 shares during the period. Finally, Rialto Wealth Management LLC bought a new position in Danaher during the fourth quarter worth $34,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 2.1 %

Shares of DHR opened at $205.69 on Friday. The stock has a fifty day moving average price of $214.57 and a two-hundred day moving average price of $236.64. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The company has a market cap of $147.01 billion, a price-to-earnings ratio of 38.96, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the business posted $2.09 EPS. Analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is currently 24.24%.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on DHR. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research report on Friday, December 13th. Barclays reduced their price objective on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Citigroup lowered their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Finally, Robert W. Baird reduced their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $278.24.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.